Financials and Corporate

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced the appointment of six leading experts to its newly formed Strategic Advisory Board (SAB). The SAB will work with...

Acceleration of becoming a fully integrated oncology-focused biotech company through a recent landmark deal with AstraZeneca Expansion of oncology development collaboration with AstraZeneca validates...

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...

Innate Pharma acquires US and EU rights to commercialize Lumoxiti to become a fully-integrated oncology-focused biotech AstraZeneca obtains full oncology rights to monalizumab AstraZeneca gains access...

Preliminary anti-tumor activity for lead asset, monalizumab, in combination with cetuximab in advanced head and neck cancer and durvalumab in microsatellite-stable colorectal cancer presented at...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced a change to its 2018 financial calendar. The financial statements as of June 30, 2018 will be issued on September...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces the results of the voting by shareholders at the Annual General Meeting (“AGM”) which took place on May 29, 2018, in Marseille, France...

Cash, cash equivalents and financial assets of the Company amounted to €153.8 million* Significant momentum across the portfolio, with good progress on the joint monalizumab program with AstraZeneca...

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 29, 2018, at 10:00 am in its headquarters, 117 avenue de Luminy...

Innate Pharma presents a clinical update on its broad and diverse development portfolio of first- or best-in-class antibodies in immuno-oncology Update on the development program with AstraZeneca on...